Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 39Terminated 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Head & Neck 1Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × perifosine × Clear all
NCT01002248 2018-02-09

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

AEterna Zentaris

Phase 3 Terminated
135 enrolled
Plasma cell

Multiple Myeloma

NCT00058214 2015-02-23

Perifosine in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled 5 charts
Genitourinary

Prostatic Neoplasms

NCT00062387 2013-06-03

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡